KELLY LOCK: Open Payments
NPI 1003828575 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$687 in 25 payments from 10 companies in 2025. Trend: 2023 $22 · 2024 $0 · 2025 $687
Food & beverage: $687
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $167 |
| GlaxoSmithKline, LLC. | 6 | $121 |
| Octapharma USA, Inc. | 1 | $92 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $77 |
| Regeneron Healthcare Solutions, Inc. | 2 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Amgen Inc. | 2 | $35 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Novartis Pharmaceuticals Corporation | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
Products named: TEZSPIRE, TRELEGY ELLIPTA, CUTAQUIG, NEFFY, DUPIXENT, TAKHZYRO, Xolair, AIRSUPRA.
Industry payments across TX — which companies pay providers there.
